{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.8","upperLimit":"49.9","value":"37.8"},{"groupId":"OG001","lowerLimit":"52.0","upperLimit":"70.1","value":"61.3"},{"groupId":"OG002","lowerLimit":"46.5","upperLimit":"76.2","value":"62.2"},{"groupId":"OG003","lowerLimit":"0.8","upperLimit":"22.1","value":"6.7"},{"groupId":"OG004","lowerLimit":"35.5","upperLimit":"64.5","value":"50.0"},{"groupId":"OG005","lowerLimit":"0.0","upperLimit":"8.0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"50"},{"groupId":"OG005","value":"44"}],"units":"Participants"}],"description":"Objective Response Rate (ORR) is defined as the number of randomized participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on IRC\\\\\\[using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\\\\\\], divided by the number of all randomized participants.\n\nComplete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\\\\<10 mm.\n\nPartial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg","id":"OG000","title":"Cohort 1: Nivolumab Monotherapy"},{"description":"Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg","id":"OG001","title":"Cohort 2: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg"},{"description":"Nivolumab 3 mg/kg Q2W with Ipilimumab 1 mg/kg twice in six weeks Q6W","id":"OG002","title":"Cohort 3: Nivolumab 3 mg/kg Q2W with Ipilimumab 1 mg/kg Q6W"},{"description":"Cohort 4: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg + Cobimetinib 60 mg","id":"OG003","title":"Cohort 4: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg + Cobimetinib 60 mg"},{"description":"Nivolumab 240 mg + BMS-986016 80 mg","id":"OG004","title":"Cohort 5: Nivolumab 240 mg + BMS-986016 80 mg"},{"description":"Nivolumab FD + Daratumumab 16 mg/kg","id":"OG005","title":"Cohort 6: Nivolumab FD + Daratumumab 16 mg/kg"}],"paramType":"NUMBER","populationDescription":"All treated participants. As pre-specified only applicable for Cohort 1, 2, 3, 4, 5 and 6","reportingStatus":"POSTED","timeFrame":"From date of randomization to the date of objectively documented progression or the date of subsequent systemic cancer therapy, whichever occurs first (Up to approximately 127 months)","title":"Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Independent Review Committee (IRC)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}